After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer and submitted it to NICE.
The FDG has been sent to consultees for this appraisal who have 5 working days to advise if they wish to appeal against it and/or notify us of any factual errors. If an intent to appeal is submitted the consultees will have an additional 10 working days to submit their appeal. The FDG has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FDG may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
NICE has been made aware of some inconsistencies in our recent communication regarding the appeal process for this appraisal.
As a result, the publication of final guidance will be delayed and consultees will have the opportunity to submit appeals until 5pm Thursday 10 July.